No abstract

Background The non-invasive detection of coronary allograft vasculopathy remains a challenge, and there is no consensus about which technique should be used. The hypersensitivity to vasodilator drugs (such as adenosine) of heart transplant recipients may have limited the use of stress cardiovascular magnetic resonance imaging (stress-CMR) in this group of patients. Regadenoson is a more specific agonist of adenosine receptors. There is still little data on its safety profile and the hemodynamic response it causes in these patients. Purpose We aimed to observe safety and hemodynamic response to regadenoson in heart transplant recipients. Methods We studied 505 consecutive patients (22 transplanted and 483 non-transplanted) who underwent stress-CMR between 06/06/2017 and 10/10/2019. We compared the hemodynamic response (blood pressure and heart rate) and the adverse effects and symptoms caused by regadenoson in both groups. Student t test and χ2 were used to compare the continuous and the qualitative variables between both groups, respectively. Results In transplant patients there were no events requiring finalization of the test (e.g. atrioventricular block, symptomatic arterial hypotension or poor tolerance to the symptomatic response to regadenoson). There were no differences in the incidence of symptoms after drug administration in transplanted versus non-transplanted patients (50% vs. 50.4%, p=0.97), and all of those symptoms were transient and well tolerated. Transplant recipients presented an attenuated hemodynamic response compared to non-transplanted patients (Table 1). Conclusions Stress-CMR with regadenoson is a safe and well tolerated technique in heart transplant recipients. In this group of patients, the hemodynamic response is blunted compared to non-transplanted patients. This lower response has been previously described in obese and diabetic patients, and it does not appear to affect the performance of the test. Further studies should confirm these findings. Funding Acknowledgement Type of funding source: None

Primary cardiac tumors are extremely rare. Incidence is approximately 0.017% of all primary tumors. Spindle cell sarcoma is the rarest, with only four cases reported and there are no guidelines for treating this condition. Cardiac sarcomas have symptoms by different mechanisms including obstruction, local invasion, and embolisms and in some cases the first manifestation could be a sudden cardiac death. Diagnosis is made with imaging techniques such as echocardiogram, cardiac computed tomography (CT), and magnetic resonance imaging (MRI) and confirmed with tissue biopsy. Patients with malignant tumors have a poor prognosis with an average mean survival of 6 months. Complete resection of the tumor remains the best treatment available. Spindle cell sarcoma may present with few symptoms and may remain silent until an advanced stage, thus limiting the few therapeutic options available.